erlotinib
埃罗替尼
常用释义
英式发音
美式发音
基本释义
- 埃罗替尼
例句
-
1·Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome.肺癌中埃罗替尼—结果的分子和临床预测。
-
2·In addition, erlotinib is an oral agent, so it is more convenient to administer than IV chemotherapy.此外，埃罗替尼是一种口服药，因此，在给药方面较静脉注射化疗药物更为方便。
-
3·Grade 3 or greater elevations of AST were reported in 11 and 8% of patients receiving erlotinib and placebo, respectively.应用厄罗替尼布和安慰剂组都有11(8%)名患者出现3级或更高的AST升高。
-
4·Erlotinib is also being evaluated in combination with capecitabine in patients who failed first-line therapy with gemcitabine.厄罗替尼布联合卡培他滨同样用于一线药物吉西他滨治疗失败的患者。
-
5·ObjectiveTo evaluate the efficacy, clinical benefits and toxicities of gemcitabine combined with erlotinib for advanced pancreatic cancer.目的观察吉西他滨联合厄洛替尼方案治疗进展期胰腺癌的疗效、临床获益反应和毒性反应。
-
6·The response rate to erlotinib therapy was similar in patients with tumor-only mutations and in those with tumor and serum mutations (67%).对埃罗替尼治疗的反应率，仅在肿瘤组织中存在变异的患者和那些肿瘤和血浆中均存在变异的患者是相似的(67%)。
-
7·The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。
-
8·To evaluate the clinical efficacy and the security of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer and COPD.评价单药厄洛替尼治疗晚期非小细胞肺癌合并COPD患者的疗效和安全性。
-
9·Conclusion For elderly patients with advanced non-small cell lung cancer and COPD, the use of erlotinib might achieve better security and effectiveness.结论厄洛替尼单药对晚期非小细胞肺癌合并COPD的患者不良反应小，耐受性好，疗效可接受。
-
10·For example, the use of bevacizumab for colorectal cancer and erlotinib for lung cancer in the United States was 10 times higher than the European average.例如，美国应用贝伐单抗治疗直肠结肠癌以及埃罗替尼治疗肺癌是欧洲平均水平的10倍。